Zihipp and EOFlow Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
- Establishment of Joint Venture Company named SanPlena in the US - Drug-device combination of EOFlow’s smart wearable drug delivery platform and novel gut peptide derivatives developed by a team led by Prof. Sir Stephen Bloom of Zihipp and Imperial College London...
Zihipp secures £3.3m Series A financing led by Mubadala to develop obesity and diabetes treatments
Zihipp Limited, a UK-based biopharmaceutical company focused on the development of peptide hormones for the treatment of diabetes and obesity, announces it has completed a £3.3 million Series A financing round. The investment was led by Mubadala Investment Company, an investment and development company owned by the Government of Abu Dhabi.
Mubadala Investment Company, through its Mubadala Healthcare investment arm, owns a number of UAE facilities focused on treating obesity and diabetes, including the Imperial College London Diabetes Centre in Al Ain and Abu Dhabi.
Zihipp will use the funds to develop a pipeline of oxyntomodulin and PYY peptides originating in the laboratory of Professor Sir Stephen Bloom FRS at Imperial College London.
Zihipp signs exclusive license and option agreements for Imperial College obesity and diabetes programmes
Zihipp Limited, a UK-based biopharmaceutical company focused on the development of peptide hormones for the treatment of diabetes and obesity, announces it has signed an exclusive license and option agreements with Imperial College London.
The exclusive license includes the pre-clinical and clinical data packages for two oxyntomodulin and PYY analogue programmes which have successfully completed phase I clinical trials, along with several GLP-1, PYY and oxyntomodulin discovery programmes.